We are live on ! Find out more
AKYA

Akoya BioSciences

Delisted

AKYA was delisted on the 7th of July, 2025.

46 hedge funds and large institutions have $121M invested in Akoya BioSciences in 2022 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 19 increasing their positions, 15 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

27% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 15

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

2% more funds holding

Funds holding: 4546 (+1)

0.23% more ownership

Funds ownership: 32.62%32.85% (+0.23%)

29% less capital invested

Capital invested by funds: $169M → $121M (-$48.4M)

97% less call options, than puts

Call options by funds: $13K | Put options by funds: $396K

Holders
46
Holders Change
+1
Holders Change %
+2.22%
% of All Funds
0.73%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.05%
New
6
Increased
19
Reduced
15
Closed
5
Calls
$13K
Puts
$396K
Net Calls
-$383K
Net Calls Change
-$383K
Name Holding Trade Value Shares
Change
Change in
Stake
HEC
1
Hudson Executive Capital
New York
$26.9M +$525K +45,305 +2%
BWLSA
2
Blue Water Life Science Advisors
California
$23M +$4.38M +377,861 +22%
BOTOTLSJU
3
Board of Trustees of The Leland Stanford Junior University
California
$17.3M -$611K -52,695 -3%
BlackRock
4
BlackRock
New York
$8.54M +$125K +10,737 +1%
Vanguard Group
5
Vanguard Group
Pennsylvania
$7.7M +$300K +25,845 +4%
Millennium Management
6
Millennium Management
New York
$7.44M +$1.07M +91,944 +16%
Allspring Global Investments
7
Allspring Global Investments
North Carolina
$5.29M -$88.4K -7,622 -2%
FAM
8
Fred Alger Management
New York
$2.99M -$17.8K -1,537 -0.6%
ETC
9
Exchange Traded Concepts
Oklahoma
$2.19M -$97.4K -8,398 -4%
Legal & General Group
10
Legal & General Group
United Kingdom
$2.15M -$78.8K -6,799 -3%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$2.08M +$69.4K +5,986 +3%
State Street
12
State Street
Massachusetts
$2M +$315K +27,194 +18%
CS
13
Candriam SCA
Luxembourg
$1.75M +$1.26M +109,000 +217%
PHP
14
Parkman Healthcare Partners
Connecticut
$1.65M +$294K +25,321 +20%
OCM
15
Osterweis Capital Management
California
$1.39M
Wells Fargo
16
Wells Fargo
California
$1.31M +$11.8K +1,021 +0.9%
Northern Trust
17
Northern Trust
Illinois
$1.16M -$41.2K -3,555 -3%
Ameriprise
18
Ameriprise
Minnesota
$1.06M -$6.9K -595 -0.6%
Fidelity Investments
19
Fidelity Investments
Massachusetts
$869K +$4.01K +346 +0.4%
RI
20
RTW Investments
New York
$854K -$259K -22,324 -22%
Charles Schwab
21
Charles Schwab
California
$741K +$84K +7,243 +12%
Bank of New York Mellon
22
Bank of New York Mellon
New York
$511K +$105K +9,027 +24%
Morgan Stanley
23
Morgan Stanley
New York
$444K +$137K +11,786 +41%
Qube Research & Technologies (QRT)
24
Qube Research & Technologies (QRT)
United Kingdom
$309K +$100K +8,652 +44%
N
25
Nuveen
North Carolina
$230K

AKYA Hedge Fund Activity: Q1 2022 in Review

46 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Akoya BioSciences (AKYA) for Q1 2022, worth a combined $121M — down 29% from $169M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new AKYA positions and 5 closed out — a net gain of 1 holder — while 19 added to existing stakes and 15 trimmed.

The largest buyer was Blue Water Life Science Advisors, adding an estimated $4.38M. The largest seller was VR Adviser, exiting entirely with an estimated $6.12M sold.

  • 46 institutional investors held Akoya BioSciences (AKYA) as of Q1 2022, up from 45 in Q4 2021.
  • Funds reported $121M of Akoya BioSciences stock for Q1 2022, down 29% quarter-over-quarter.
  • 6 funds opened new Akoya BioSciences positions in Q1 2022 and 5 closed out, a net change of +1 holder.
  • The largest Akoya BioSciences buyer in Q1 2022 was Blue Water Life Science Advisors, an estimated $4.38M added.
  • The largest Akoya BioSciences seller in Q1 2022 was VR Adviser, an estimated $6.12M sold.

Based on aggregated 13F filings for Q1 2022.